For many years the prevailing view held that once nerve pathways in the brain or spinal cord are cut, they cannot regenerate, leaving paralysis permanent. A recent study from the University of Cambridge disputes that notion, showing that human nerve cells retain a latent capacity to regrow under certain conditions.
A Human‑Only Laboratory Model
The Cambridge team, led by Andras Lakatos, built their experiments around pea‑sized organoids derived entirely from human stem cells. These miniature structures mimic separate brain and spinal cord tissues. After growing the organoids independently, the researchers observed axons — the long nerve fibres — extending from the brain‑like organoid, crossing a gap, and establishing functional links with the spinal‑cord organoid. The newly formed connections were capable of eliciting muscle contractions, demonstrating that the regrown axons were not merely present but active.
Identifying a Developmental Timer
Beyond documenting regrowth, the investigators uncovered an intrinsic timing mechanism within human neurons. Cells that are relatively young — up to approximately day 150 of their development — retain the ability to repair damaged axons. After this point, a genetic switch embedded in maturing cells sharply curtails regenerative potential. This decline is not caused by the severity of injury or by scar tissue; it appears to be a programmed loss of capacity.
Reversing the Switch
By mapping the gene network that governs this switch, the researchers pinpointed key regulatory molecules. Experimentally inhibiting these regulators restored the neurons’ ability to extend axons. In parallel tests, an existing drug called lynestrenol enhanced axon regrowth. The authors stress that lynestrenol is unlikely to become a definitive therapy, but its effect proves a principle: human neurons can be directly targeted and persuaded to regenerate.
Why a Human Model Matters
Much of the prior research on nerve regeneration relied on rodent models. Mouse and rat neurons differ sufficiently from human neurons that a treatment effective in animals often fails in people. The Cambridge approach bypasses this limitation by using human tissue from the outset, providing a more relevant platform for testing potential interventions.
Broader Implications for Neurological Disease
The findings extend beyond spinal cord injury. The same failure of axons to regrow underlies conditions such as motor neurone disease and multiple sclerosis. In each case, the core problem is the loss of axonal continuity. The study shows that this blockage is not absolute; it is governed by a switch that can be flipped, suggesting a common point of intervention across several devastating disorders.
From Discovery to Therapy
The researchers acknowledge that translating these laboratory results into clinical treatments will require considerable time and further work. Nonetheless, the study dismantles the long‑held assumption that damage to the human central nervous system is permanently irreversible. By creating a functional, human‑based test system — a pea‑sized brain and spinal cord grown from stem cells that forms working circuits — the team has demonstrated that regeneration can be observed, halted, and then re‑induced after blocking the genetic brakes.
A New Question for the Field
While no immediate cure is on the horizon and lynestrenol is viewed only as a starting point, the discovery shifts the focus of inquiry. The question is no longer whether human neurons possess the ability to regrow; it is now how to sustain the regenerative state by keeping the genetic switch activated.
